# Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea

> **NCT01642589** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 300 (actual)

## Conditions studied

- Meningitis
- Meningococcal Disease

## Interventions

- **BIOLOGICAL:** Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)
- **BIOLOGICAL:** Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed

## Key facts

- **NCT ID:** NCT01642589
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2013-01
- **Final completion:** 2013-06
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2013-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01642589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01642589, "Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01642589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*